Home
INVA
INVA News

Latest Innoviva Inc. (INVA) News on September 18, 2025

MT Newswires

3 months ago

Innoviva Says FDA Grants Priority Review to Zoliflodacin NDA for Treating Gonorrhea; Shares Up Pre-Bell

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

Business Wire

3 months ago

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

Argus Research

3 months ago

INVA: Raising target price to $23.00

MT Newswires

3 months ago

Innoviva Says FDA Accepts New Drug Application for Zoliflodacin

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

Business Wire

3 months ago

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

Innoviva to Participate in Upcoming Investor Conferences

Business Wire

3 months ago

Innoviva to Participate in Upcoming Investor Conferences

Argus Research

4 months ago

INVA: Raising target price to $20.00

ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections

Business Wire

4 months ago

ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections

Argus Research

4 months ago

INVA: Lowering target price to $19.00

Innoviva, Inc. (INVA): Among Stocks with Insanely High PE Ratios Insiders Are Selling

Insider Monkey

4 months ago

Innoviva, Inc. (INVA): Among Stocks with Insanely High PE Ratios Insiders Are Selling

Associated Press Finance

4 months ago

Innoviva: Q1 Earnings Snapshot

Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress

Business Wire

4 months ago

Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress

Argus Research

4 months ago

INVA: Raising target price to $20.00

Argus Research

5 months ago

INVA: What does Argus have to say about INVA?

Argus Research

5 months ago

INVA: Raising target price to $19.00

Are Innoviva, Inc.'s (NASDAQ:INVA) Mixed Financials Driving The Negative Sentiment?

Simply Wall St.

5 months ago

Are Innoviva, Inc.'s (NASDAQ:INVA) Mixed Financials Driving The Negative Sentiment?

Argus Research

5 months ago

INVA: Lowering target price to $18.00

Argus Research

6 months ago

INVA: Raising target price to $19.00

Argus Research

6 months ago

INVA: What does Argus have to say about INVA?

Victoria’s Secret, Bitdeer, and More Stocks See Activist Action

Barrons.com

6 months ago

Victoria’s Secret, Bitdeer, and More Stocks See Activist Action

WEX, Lamb Weston, and More Stocks See Action From Activist Investors

Barrons.com

6 months ago

WEX, Lamb Weston, and More Stocks See Action From Activist Investors

MT Newswires

6 months ago

Armata Pharmaceuticals Enters $10 Million Secured Credit Agreement with Innoviva

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

PR Newswire

6 months ago

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

MT Newswires

6 months ago

Innoviva Insider Sold Shares Worth $28,395,442, According to a Recent SEC Filing

Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference

Business Wire

6 months ago

Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference

Argus Research

6 months ago

INVA: Lowering target price to $18.00

Innoviva Full Year 2024 Earnings: EPS: US$0.37 (vs US$2.75 in FY 2023)

Simply Wall St.

7 months ago

Innoviva Full Year 2024 Earnings: EPS: US$0.37 (vs US$2.75 in FY 2023)

Associated Press Finance

7 months ago

Innoviva: Q4 Earnings Snapshot

Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

Business Wire

7 months ago

Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

Argus Research

7 months ago

INVA: What does Argus have to say about INVA?

Argus Research

7 months ago

INVA: What does Argus have to say about INVA?

Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Business Wire

7 months ago

Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Argus Research

7 months ago

INVA: Lowering target price to $19.00

Argus Research

8 months ago

INVA: What does Argus have to say about INVA?

Argus Research

8 months ago

INVA: Raising target price to $20.00

Argus Research

8 months ago

INVA: Raising target price to $19.00

Innoviva's (NASDAQ:INVA) investors will be pleased with their 26% return over the last five years

Simply Wall St.

9 months ago

Innoviva's (NASDAQ:INVA) investors will be pleased with their 26% return over the last five years

Argus Research

9 months ago

INVA: What does Argus have to say about INVA?

Argus Research

9 months ago

INVA: Lowering target price to $19.00

Innoviva enters distribution, license agreement with Basilea for Zevtera

TipRanks

9 months ago

Innoviva enters distribution, license agreement with Basilea for Zevtera

MT Newswires

9 months ago

Innoviva to Sell Basilea Pharmaceutica's MRSA Antibiotic Zevtera in US Under Exclusive Deal

Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

Business Wire

9 months ago

Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

Argus Research

9 months ago

INVA: What does Argus have to say about INVA?

Argus Research

9 months ago

INVA: What does Argus have to say about INVA?

Argus Research

10 months ago

INVA: What does Argus have to say about INVA?

Innoviva to Participate in the Citi 2024 Global Healthcare Conference

Business Wire

10 months ago

Innoviva to Participate in the Citi 2024 Global Healthcare Conference

Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity

PR Newswire

10 months ago

Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity

Argus Research

10 months ago

INVA: Raising target price to $21.00

Innoviva to Participate in the UBS Global Healthcare Conference

Business Wire

10 months ago

Innoviva to Participate in the UBS Global Healthcare Conference

Innoviva Third Quarter 2024 Earnings: EPS: US$0.019 (vs US$1.26 in 3Q 2023)

Simply Wall St.

10 months ago

Innoviva Third Quarter 2024 Earnings: EPS: US$0.019 (vs US$1.26 in 3Q 2023)

Associated Press Finance

10 months ago

Innoviva: Q3 Earnings Snapshot

Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress

Business Wire

10 months ago

Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress

Argus Research

10 months ago

INVA: Lowering target price to $20.00

Argus Research

a year ago

INVA: Raising target price to $21.00

Innoviva, Inc.'s (NASDAQ:INVA) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Simply Wall St.

a year ago

Innoviva, Inc.'s (NASDAQ:INVA) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Innoviva to Participate in Upcoming Investor Conferences

Business Wire

a year ago

Innoviva to Participate in Upcoming Investor Conferences

Argus Research

a year ago

INVA: Raising target price to $20.00

Argus Research

a year ago

INVA: What does Argus have to say about INVA?

Associated Press Finance

a year ago

Innoviva: Q2 Earnings Snapshot

Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress

Business Wire

a year ago

Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress

Argus Research

a year ago

INVA: Raising target price to $19.00

Innoviva (NASDAQ:INVA) shareholders have earned a 36% return over the last year

Simply Wall St.

a year ago

Innoviva (NASDAQ:INVA) shareholders have earned a 36% return over the last year

Argus Research

a year ago

INVA: Raising target price to $18.00

Argus Research

a year ago

INVA: What does Argus have to say about INVA?

Apple downgraded, Kroger upgraded: Wall Street's top analyst calls

The Fly

a year ago

Apple downgraded, Kroger upgraded: Wall Street's top analyst calls

Calculating The Fair Value Of Innoviva, Inc. (NASDAQ:INVA)

Simply Wall St.

a year ago

Calculating The Fair Value Of Innoviva, Inc. (NASDAQ:INVA)

Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Business Wire

a year ago

Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

MT Newswires

a year ago

Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment

GuruFocus.com

a year ago

Innoviva Inc (INVA) Reports First Quarter 2024 Earnings: A Detailed Analysis

Innoviva First Quarter 2024 Earnings: EPS: US$0.58 (vs US$0.51 in 1Q 2023)

Simply Wall St.

a year ago

Innoviva First Quarter 2024 Earnings: EPS: US$0.58 (vs US$0.51 in 1Q 2023)

Associated Press Finance

a year ago

Innoviva: Q1 Earnings Snapshot

Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress

Business Wire

a year ago

Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress

Innoviva to Participate in the BofA Securities Health Care Conference

Business Wire

a year ago

Innoviva to Participate in the BofA Securities Health Care Conference

Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Business Wire

a year ago

Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Argus Research

a year ago

INVA: Raising target price to $16.00

Should Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Simply Wall St.

a year ago

Should Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

PR Newswire

2 years ago

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

Associated Press Finance

2 years ago

Innoviva: Q4 Earnings Snapshot

Innoviva Inc (INVA) Reports Growth Amidst Challenges in Q4 and Full Year 2023 Financial Results

GuruFocus.com

2 years ago

Innoviva Inc (INVA) Reports Growth Amidst Challenges in Q4 and Full Year 2023 Financial Results

Business Wire

2 years ago

Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

Jim Simons Bolsters Position in Innoviva Inc with Recent Acquisition

GuruFocus.com

2 years ago

Jim Simons Bolsters Position in Innoviva Inc with Recent Acquisition

Orion Insiders Added US$653.2k Of Stock To Their Holdings

Simply Wall St.

2 years ago

Orion Insiders Added US$653.2k Of Stock To Their Holdings

Dyne Therapeutics to Present at February Investor Conferences

GlobeNewswire

2 years ago

Dyne Therapeutics to Present at February Investor Conferences

Should You Invest in Perion Network (PERI) Based on Bullish Wall Street Views?

Zacks

2 years ago

Should You Invest in Perion Network (PERI) Based on Bullish Wall Street Views?

Ahead of Sally Beauty (SBH) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Zacks

2 years ago

Ahead of Sally Beauty (SBH) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics

Netflix and Vita Coco have been highlighted as Zacks Bull and Bear of the Day

Zacks

2 years ago

Netflix and Vita Coco have been highlighted as Zacks Bull and Bear of the Day

Is Cracker Barrel Old Country Store, Inc.'s (NASDAQ:CBRL) 19% ROE Better Than Average?

Simply Wall St.

2 years ago

Is Cracker Barrel Old Country Store, Inc.'s (NASDAQ:CBRL) 19% ROE Better Than Average?

Reflecting On Specialty Retail Stocks’ Q3 Earnings: Sally Beauty (NYSE:SBH)

StockStory

2 years ago

Reflecting On Specialty Retail Stocks’ Q3 Earnings: Sally Beauty (NYSE:SBH)

Q3 Rundown: Best Buy Co (NYSE:BBY) Vs Other Specialty Retail Stocks

StockStory

2 years ago

Q3 Rundown: Best Buy Co (NYSE:BBY) Vs Other Specialty Retail Stocks

Zacks Industry Outlook Highlights Ulta Beauty, Five Below, Arhaus and Sally Beauty

Zacks

2 years ago

Zacks Industry Outlook Highlights Ulta Beauty, Five Below, Arhaus and Sally Beauty

Unpacking Q3 Earnings: Bath and Body Works (NYSE:BBWI) In The Context Of Other Specialty Retail Stocks

StockStory

2 years ago

Unpacking Q3 Earnings: Bath and Body Works (NYSE:BBWI) In The Context Of Other Specialty Retail Stocks

First Financial Bancorp (FFBC) Tops Q4 Earnings Estimates

Zacks

2 years ago

First Financial Bancorp (FFBC) Tops Q4 Earnings Estimates

Associated Press Finance

2 years ago

First Financial: Q4 Earnings Snapshot

First Financial Bancorp (FFBC) Reports Solid Loan Growth Amid Rising Funding Costs

GuruFocus.com

2 years ago

First Financial Bancorp (FFBC) Reports Solid Loan Growth Amid Rising Funding Costs

Analysts Estimate Sally Beauty (SBH) to Report a Decline in Earnings: What to Look Out for

Zacks

2 years ago

Analysts Estimate Sally Beauty (SBH) to Report a Decline in Earnings: What to Look Out for

4 Retail-Miscellaneous Stocks With Potential to Beat Industry Blues

Zacks

2 years ago

4 Retail-Miscellaneous Stocks With Potential to Beat Industry Blues

10 Best Small Cap Chemical Stocks to Buy

Insider Monkey

2 years ago

10 Best Small Cap Chemical Stocks to Buy

Argus Research

2 years ago

Daily – Vickers Top Buyers & Sellers for 01/25/2024

Dorchester Minerals LP's Dividend Analysis

GuruFocus.com

2 years ago

Dorchester Minerals LP's Dividend Analysis

GuruFocus.com

2 years ago

First Busey Corp (BUSE) Reports Mixed Q4 Earnings Amid Strategic Acquisitions and Balance Sheet ...

Share on Social Networks: